Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients.

Cystic fibrosis (CF) is characterized by chronic lung inflammation leading to airways obstruction. Bronchodilators, particularly short-acting beta2-agonists, are, therefore, often used by CF patients. The aim of this study was to evaluate, prospectively, the effects of the long-acting beta2-agonist salmeterol in adult CF patients. Twenty six patients with CF (10 males and 16 females; mean age (+/-SEM) 28+/-2 yrs) with mild-to-moderate airways obstruction (baseline forced expiratory volume in one second/forced vital capacity (FEV1/FVC) 56+/-2%) were monitored in an open, cross-over trial for 4 weeks by means of peak expiratory flow rates (PEFR), self-recorded symptom scores and body plethysmography. During a 2 week run-in period, all patients continued their treatment, including regular short-acting beta2-agonists. In weeks 3 and 4, short-acting beta2-agonists were replaced by the long-acting beta2-agonist, salmeterol (50 microg b.i.d.). Salmeterol produced a significant increase in PEFR compared to the run-in period (morning 375+/-23 vs 332+/-23 L x min(-1), deltaPEFR +15.1+/-3.1%, p<0.003; evening 384+/-24 vs 349+/-24 L x min(-1), deltaPEFR +11.7+/-2.4%, p<0.04). Similarly, patients reported lower symptom scores, e.g. less dyspnoea during the day, fewer nocturnal awakenings, less intense cough, and fewer unscheduled puffs of short-acting beta2-agonists. Thus, the long-acting beta2-agonist salmeterol provided clinical benefit to a majority of adult cystic fibrosis patients with airways obstruction. These short-term results are promising enough to set up long-term controlled studies.

[1]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[2]  D. Cockcroft,et al.  Functional antagonism: tolerance produced by inhaled beta 2 agonists. , 1996, Thorax.

[3]  E. Israel,et al.  Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. , 1996, The New England journal of medicine.

[4]  M. Hodson,et al.  Quality of life in adults with cystic fibrosis. , 1996, Thorax.

[5]  L. Jacques,et al.  Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group. , 1996, The European respiratory journal.

[6]  P. Sammut,et al.  The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. , 1996, American journal of respiratory and critical care medicine.

[7]  B. Lipworth,et al.  Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. , 1996, Thorax.

[8]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[9]  G. Cropp.  Effectiveness of bronchodilators in cystic fibrosis. , 1996, The American journal of medicine.

[10]  P. O'Byrne,et al.  The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. , 1996, American journal of respiratory and critical care medicine.

[11]  P. König,et al.  Short‐term and long‐term effects of albuterol aerosol therapy in cystic fibrosis: A preliminary report , 1995, Pediatric pulmonology.

[12]  M. Cazzola,et al.  Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. , 1995, Respiratory medicine.

[13]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[14]  M. Konstan,et al.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. , 1994, American journal of respiratory and critical care medicine.

[15]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[16]  Salmeterol in the treatment of asthma. , 1994, Australian family physician.

[17]  H. Magnussen,et al.  Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. , 1993, The American review of respiratory disease.

[18]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[19]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[20]  J. Tomashefski,et al.  The pathology of cystic fibrosis , 1993 .

[21]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[22]  F. Dekker,et al.  Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction. , 1992, Thorax.

[23]  J. Malo,et al.  A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. , 1991, The American review of respiratory disease.

[24]  C. Madden.  Regular inhaled beta-agonist treatment in bronchial asthma , 1991 .

[25]  E. Mellits,et al.  A controlled trial of long-term bronchodilator therapy in cystic fibrosis. , 1991, Chest.

[26]  S. Holgate,et al.  Protection against allergen-induced asthma by salmeterol , 1990, The Lancet.

[27]  D. Dacruz,et al.  Guidelines for management of asthma. , 1990, BMJ.

[28]  J. Hedner,et al.  Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. , 1990, The American review of respiratory disease.

[29]  J. Hedner,et al.  Inhaled Salmeterol and Salbutamol in Asthmatic Patients , 1990 .

[30]  Charles R.scriver,et al.  The Metabolic basis of inherited disease , 1989 .

[31]  D. Raeburn.  Bronchodilator therapy in cystic fibrosis: for better or worse? , 1988, Medical hypotheses.

[32]  P. König,et al.  A longitudinal study of bronchodilator responsiveness in cystic fibrosis. , 1985, The American review of respiratory disease.

[33]  G. Polgar,et al.  Bronchodilators increase airway instability in cystic fibrosis , 1985, The American review of respiratory disease.

[34]  Surveillance for respiratory hazards in the occupational setting [American Thoracic Society]. , 1982, The American review of respiratory disease.

[35]  M. Tobin,et al.  Atopy and bronchial reactivity in older patients with cystic fibrosis. , 1980, Thorax.

[36]  D. Stableforth,et al.  Reversible airway obstruction in cystic fibrosis. , 1980, Thorax.

[37]  J. Hirsch,et al.  Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. , 1975, The American review of respiratory disease.

[38]  G. Ehrlich,et al.  The Metabolic Basis Of Inherited Disease. , 1973 .

[39]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[40]  D. Cockcroft,et al.  Functional antagonism : tolerance produced by inhaled 32 agonists , 2022 .